MOTS-C in Hue: Mitochondrial-Derived Peptide Biology and Proposed Metabolic Signaling Pathways

Featured Answer: What Is MOTS-c and How Might It Influence Metabolism?

MOTS-c, short for mitochondrial open reading frame of the 12S rRNA-c, is a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame within the mitochondrial MT-RNR1 region. Unlike conventional signaling proteins encoded by nuclear DNA, MOTS-c originates from the mitochondrial genome and has been investigated as a possible messenger linking mitochondrial activity with cellular and whole-body metabolic responses.

The best-known proposed pathway involves changes in folate-cycle activity and de novo purine biosynthesis. In experimental systems, these changes can increase the abundance of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), a metabolite associated with activation of AMP-activated protein kinase (AMPK). AMPK is a central cellular energy sensor that coordinates energy use, nutrient metabolism, and adaptive responses to metabolic stress.

Other experimental research suggests that MOTS-c may move into the nucleus under stress-related conditions and influence the expression of genes involved in cellular adaptation. These findings provide a plausible framework for studying mitochondrial-to-nuclear communication. However, the precise mechanisms, relevance to human physiology, and therapeutic implications remain incompletely established. [1] [2]

1. Introduction: Why Mitochondrial Signaling Matters

Mitochondria are widely known for their role in producing ATP through oxidative phosphorylation. Yet their biological functions extend beyond energy production. They also participate in nutrient sensing, redox regulation, calcium handling, stress responses, and communication with the nucleus.

This communication is often described as mitochondrial retrograde signaling: information originating in mitochondria influences cellular processes and gene expression outside the organelle. Such signals can include changes in metabolites, reactive oxygen species, calcium, and stress-responsive proteins.

Mitochondrial-derived peptides (MDPs) have emerged as another potential component of this communication network. These short peptides are encoded by small open reading frames within mitochondrial DNA. The group includes humanin, small humanin-like peptides, and MOTS-c, each with distinct proposed biological activities.

MOTS-c is particularly interesting because early studies connected it with skeletal muscle metabolism, insulin sensitivity, and AMPK-associated signaling. Subsequent studies have explored possible roles in exercise responses, metabolic stress, aging, and gene regulation.

These research directions should not be collapsed into a single claim that MOTS-c improves human metabolism. The scientifically useful question is more specific: what mechanisms have been observed, in which experimental systems, and how much evidence supports their relevance to humans?

2. What Is MOTS-c?

MOTS-c is a 16-amino-acid peptide identified in 2015. Its name refers to a mitochondrial open reading frame associated with the 12S ribosomal RNA region, encoded by the mitochondrial MT-RNR1 gene.

Most familiar peptide hormones are encoded by nuclear genes, translated through conventional cellular pathways, and processed into biologically active forms. MOTS-c differs because its coding sequence is associated with mitochondrial DNA. Its identification helped expand the concept of mitochondrial genetics beyond the traditional view that mitochondrial DNA primarily encodes components of the respiratory chain and mitochondrial translation machinery.

MOTS-c is part of the broader mitochondrial-derived peptide research field. It is not the same molecule as humanin, and findings for one MDP should not automatically be attributed to another. Their sequences, proposed mechanisms, and experimental evidence differ.

The distinction between endogenous and exogenous MOTS-c

Endogenous MOTS-c refers to the peptide naturally produced by the body and measured in biological samples such as plasma, muscle, or other tissues.

Exogenous MOTS-c refers to peptide supplied from outside the body in an experimental intervention.

This distinction is fundamental. An association between endogenous MOTS-c and a metabolic characteristic does not show that administering MOTS-c will change that characteristic. The naturally occurring peptide may be a cause, a response to physiological stress, a correlated biomarker, or part of a more complex biological process.

Similarly, a change in endogenous MOTS-c after exercise does not establish that an external MOTS-c preparation can reproduce the timing, tissue distribution, concentration, or wider physiological effects of exercise.

3. The Proposed Folate–Purine–AMPK Pathway

The folate–purine–AMPK pathway is the central mechanistic model associated with the original MOTS-c research. It connects changes in nucleotide metabolism with a cellular energy-sensing system.

Step 1: Effects on folate-cycle activity

The folate cycle supports one-carbon metabolism, which is involved in nucleotide synthesis and other essential biochemical reactions. Folate-dependent reactions contribute to the production of building blocks needed for DNA and RNA synthesis.

In the original experimental work, MOTS-c was associated with inhibition or disruption of folate-cycle activity. The resulting metabolic changes affected the pathway linked to de novo purine biosynthesis.

This should not be interpreted as evidence that MOTS-c simply improves all aspects of cellular metabolism. Changing folate or nucleotide pathways can have context-dependent effects, and the consequences may differ according to cell type, nutrient availability, exposure, and metabolic state.

Step 2: Changes in de novo purine biosynthesis

Purines are essential components of ATP, GTP, DNA, RNA, and several intracellular signaling molecules. De novo purine biosynthesis is the pathway by which cells build purine nucleotides from smaller precursor molecules.

The original MOTS-c study linked changes in the folate cycle with altered de novo purine synthesis and accumulation of AICAR-related intermediates. AICAR is also known in its phosphorylated nucleotide form as ZMP, an AMP-related molecule capable of influencing AMPK signaling.

The importance of this connection is conceptual: mitochondrial-derived signaling may affect cellular energy-sensing pathways indirectly by changing the availability of metabolic intermediates, rather than acting only through a conventional cell-surface receptor.

Step 3: AMPK activation

AMP-activated protein kinase is a conserved regulator of cellular energy balance. It responds to changes in cellular energy status and coordinates pathways that help cells match energy demand with energy supply.

When AMPK signaling increases, downstream responses can include greater glucose uptake in some contexts, changes in fatty-acid oxidation, reduced investment in certain energy-consuming biosynthetic processes, and regulation of other metabolic pathways.

The original MOTS-c study reported AMPK-associated metabolic effects and improvements in selected metabolic outcomes in experimental models. However, AMPK is influenced by many signals. Demonstrating that MOTS-c and AMPK activity change together does not by itself prove that every observed effect is mediated exclusively by AMPK.

Source: Lee et al., Cell Metabolism, 2015. Original study.

4. AMPK, Energy Balance, and Insulin Sensitivity

AMPK acts as an intracellular energy sensor. It helps coordinate metabolic responses when cells need to conserve energy, increase ATP-generating processes, or reduce selected energy-consuming activities.

Because skeletal muscle is a major site of insulin-stimulated glucose disposal, changes in muscle energy metabolism can influence whole-body glucose regulation. This helps explain why the original MOTS-c study focused on skeletal muscle as a key target tissue.

In experimental models, MOTS-c treatment was associated with protection against age-related and high-fat-diet-associated insulin resistance, as well as reduced diet-induced obesity. These observations supported the hypothesis that mitochondrial-derived peptides can influence metabolic homeostasis.

Nevertheless, AMPK activation is not a direct substitute for a clinical endpoint. An increase in AMPK-associated signaling does not automatically establish a meaningful improvement in HbA1c, diabetes complications, body composition, cardiovascular outcomes, or long-term health in humans.

The translation from cellular signaling to whole-body benefit depends on many factors, including the duration and magnitude of pathway activation, the tissues affected, compensatory responses, and the individual’s metabolic state.

5. MOTS-c and Mitochondrial Retrograde Signaling

Beyond the folate–purine–AMPK model, research has proposed that MOTS-c can participate in mitochondrial retrograde signaling. In this model, a mitochondrial-derived peptide communicates information about cellular stress or metabolic conditions to the nucleus, influencing the expression of selected genes.

A 2023 review describes experimental findings in which MOTS-c translocates to the nucleus under particular stress-related conditions and interacts with transcriptional programs associated with cellular adaptation. Reported pathways include antioxidant-response signaling and transcription factors such as NRF2 and ATF-family proteins. [2]

The proposed NRF2 connection

NRF2 is a transcription factor involved in cellular responses to oxidative and electrophilic stress. When activated, it can regulate genes containing antioxidant response elements, supporting the expression of proteins involved in cellular defense and stress adaptation.

Experimental research suggests that MOTS-c may influence NRF2-associated gene expression. This provides a possible link between mitochondrial signaling and the nucleus, where transcriptional responses can modify how cells respond to changing conditions.

However, NRF2 is regulated by numerous pathways. A reported association between MOTS-c and NRF2-related signaling does not establish that every proposed antioxidant or protective effect is directly caused by MOTS-c, nor does it demonstrate a clinically meaningful benefit in humans.

The proposed role of ATF-family transcription factors

Activating transcription factors participate in gene regulation during stress and metabolic adaptation. Experimental studies have implicated ATF-related signaling in the nuclear responses associated with MOTS-c.

These findings broaden the possible mechanism beyond a single metabolic pathway. They also increase the need for careful interpretation: a network of interacting signaling processes can produce different responses across cell types, experimental conditions, and exposure levels.

6. MOTS-c, Exercise, and Mitohormesis

Exercise places physiological demands on skeletal muscle and changes cellular energy status, redox signaling, and metabolic substrate use. Moderate, transient stress can trigger adaptive responses, a phenomenon often discussed under the term mitohormesis.

Mitohormesis describes the idea that a limited stress stimulus can activate adaptive responses that improve resilience under certain conditions. Mitochondrial-derived peptides have been investigated as possible components of this response, with MOTS-c receiving particular attention in exercise-related research.

A 2021 Nature Communications study reported that endogenous MOTS-c levels changed following exercise in a small group of healthy young male volunteers. Relative MOTS-c levels in skeletal muscle increased approximately 11.9-fold after exercise. Circulating levels increased approximately 1.6-fold during exercise and 1.5-fold after exercise, returning toward baseline after four hours of rest. [3]

These measurements suggest that MOTS-c may respond dynamically to exercise-related physiological conditions. They do not show that administering MOTS-c produces the same response or improves performance in people.

What the exercise findings can and cannot establish

• They can support: the hypothesis that endogenous MOTS-c is responsive to exercise-related physiological changes in the studied participants.
• They can motivate: further investigation into muscle metabolism, stress adaptation, and mitochondrial-to-nuclear communication.
• They cannot establish: that exogenous MOTS-c improves human endurance, strength, recovery, body composition, or metabolic health.
• They cannot replace: randomized human intervention trials that assess the effects and safety of administering the peptide.

Animal studies have reported changes in exercise capacity and metabolic adaptation after MOTS-c administration. These findings are useful for generating hypotheses, but animal physiology, experimental exposure, and outcome measures may not translate directly to humans.

7. MOTS-c and Metabolic Health: What the Animal Research Suggests

The original 2015 study reported that MOTS-c treatment protected mice against age-related and high-fat-diet-induced insulin resistance and reduced diet-induced obesity. The findings supported a role for MOTS-c in experimental metabolic regulation. [1]

Subsequent preclinical studies have explored potential effects involving glucose metabolism, adipose tissue, exercise-related adaptation, inflammation, and age-associated physiological changes.

These studies are important because they provide testable hypotheses and help identify candidate pathways for further research. However, animal models cannot establish a human therapeutic effect on their own.

Several questions remain when translating these observations:

• Does the same mechanism operate in human tissues at physiologically relevant concentrations?
• Would externally administered MOTS-c reach the relevant tissues in an active form?
• What are the peptide’s pharmacokinetics, distribution, metabolism, and clearance in humans?
• Are the observed effects reproducible across different models, laboratories, and study designs?
• Would the biological response improve a clinically meaningful outcome rather than only a laboratory marker?
• What are the short- and long-term risks, including immune responses and effects on other metabolic pathways?

Until these questions are addressed through suitable research, statements about MOTS-c as a treatment for obesity, insulin resistance, aging, or exercise performance should be described as investigational hypotheses rather than established clinical benefits.

8. Human Evidence: Endogenous MOTS-c Versus Administered MOTS-c

Human research on MOTS-c includes studies measuring naturally occurring peptide concentrations in blood or tissues. These studies are relevant to understanding human physiology, but they answer different questions from trials in which researchers administer the peptide.

For example, an observational study may compare circulating MOTS-c levels in people with and without a metabolic condition. A correlation may show that the peptide’s concentration is associated with a particular physiological state. It cannot by itself determine whether the peptide caused that state, resulted from it, or changed in response to another factor.

Likewise, an exercise study may show that endogenous MOTS-c levels change after physical activity. This does not establish the safety, pharmacokinetics, or efficacy of an injected or otherwise externally administered product.

As of the evidence reviewed for this article in October 2026, the U.S. FDA’s July 2026 advisory-committee briefing on MOTS-c-related bulk drug substances stated that adequate human data and clinical safety information for drug products containing MOTS-c-related substances were lacking. A registered Phase 2a intervention study is a separate development from a completed trial with published results. The presence of an ongoing study does not establish a treatment effect. [6]

Regulatory status is jurisdiction-specific and may change. Readers should consult current official sources rather than assuming that a research product is approved for human use.

9. What Does the Human Meta-Analysis Show?

A 2024 systematic review and meta-analysis examined associations between circulating mitochondrial-derived peptide levels and metabolic states. The analysis included seven observational studies, represented as 11 groups, with 602 participants. It reported an overall lower circulating MOTS-c concentration in the combined diabetes and obesity analysis, but subgroup findings differed. [4]

In the type 2 diabetes subgroup, the analysis reported a standardized mean difference of −0.89, with a 95% confidence interval from −1.12 to −0.65. In the obesity subgroup, the analysis reported a positive standardized mean difference of 0.51, with a 95% confidence interval from 0.21 to 0.81, after the subgroup analysis described by the authors.

The opposing directions are important. They show why it would be inaccurate to claim that circulating MOTS-c is uniformly low in every metabolic disorder or that a single blood concentration can be treated as a universal indicator of metabolic health.

Standardized mean difference expresses the difference between groups relative to variability in the measurements. It is not a percentage change, a clinical risk ratio, or evidence that increasing MOTS-c would improve health.

The authors also discussed heterogeneity among studies and differences between population groups. With a small observational evidence base, the findings should be viewed as hypothesis-generating. They do not establish causation, a diagnostic threshold, or the effectiveness of administering MOTS-c.

Sources: Lee et al.; Reynolds et al.; Zhou et al.; and the FDA’s 2026 advisory-committee materials. [1] [3] [4] [6]

10. Proposed Metabolic Signaling Pathways: Evidence and Uncertainty

The following pathways are discussed in the MOTS-c literature. They should be understood as a mixture of experimentally supported mechanisms and broader hypotheses whose importance in human physiology remains uncertain.

Folate–purine–AMPK signaling

This is the best-known pathway in the original MOTS-c model. It links changes in folate metabolism and purine synthesis to AICAR-related metabolite accumulation and AMPK-associated responses. Its main limitation is that preclinical pathway findings do not automatically translate into therapeutic outcomes in humans.

Mitochondrial-to-nuclear communication

Experimental work suggests that MOTS-c can translocate to the nucleus under certain stress-related conditions and influence gene-expression programs. This is a proposed mechanism for coordinating mitochondrial status with cellular adaptation. The tissue-specific triggers, regulation, and human relevance require further study.

NRF2-associated stress responses

NRF2-related signaling is a possible component of the nuclear response associated with MOTS-c. Because NRF2 regulates multiple antioxidant and stress-response genes, a change in this pathway can have different consequences depending on the cell and experimental setting. It should not be translated into a broad claim that MOTS-c is a proven antioxidant treatment.

Exercise-related metabolic adaptation

Endogenous MOTS-c changes have been reported in human exercise research, while administration studies in animals have explored exercise-related outcomes. These are complementary but distinct lines of evidence. Direct human intervention studies are needed to determine whether external MOTS-c changes metabolic adaptation or physical performance.

Adipose tissue and whole-body energy balance

Preclinical studies have explored possible effects on adipose tissue and energy expenditure. These findings may help explain the metabolic phenotypes observed in animal models. They do not establish that MOTS-c produces clinically meaningful weight loss in humans or that it can be used as a treatment for obesity.

11. Safety, Pharmacology, and Regulatory Considerations

A proposed biological mechanism is not a safety assessment. Before a peptide can be evaluated as a therapeutic candidate, researchers need to characterize its identity, purity, stability, pharmacokinetics, tissue exposure, biological activity, dose-response relationship, and potential adverse effects.

For MOTS-c, important unresolved questions include:

• Pharmacokinetics: How quickly is externally administered MOTS-c absorbed, distributed, metabolized, and cleared in humans?
• Immunogenicity: Could the peptide or its formulation trigger immune responses, including anti-drug antibodies?
• Off-target effects: Could effects on nucleotide metabolism or energy-sensing pathways have unintended consequences in particular tissues?
• Long-term exposure: What happens when a biologically active peptide is administered repeatedly over extended periods?
• Product quality: Does a specific product have verified identity, purity, sterility where applicable, and appropriate manufacturing controls?
• Clinical benefit-risk balance: Do any potential benefits outweigh the risks in a defined patient population?

The U.S. FDA’s July 2026 advisory-committee briefing on MOTS-c-related bulk drug substances identified gaps in characterization, human-use information, clinical and nonclinical safety information, and immunogenicity assessment. This document was prepared for an advisory proceeding; it should not be misrepresented as a final regulatory ruling or as a substitute for checking the current status in the relevant jurisdiction. [6]

Commercial availability does not demonstrate regulatory approval, and a product marketed for research does not become a validated human medicine because it is described as a naturally occurring peptide.

12. What Research Would Strengthen the Evidence?

Progress from mechanistic promise to clinical relevance requires several stages of research.

• Analytical validation: Reliable methods to identify and quantify MOTS-c in biological samples and characterize investigational preparations.
• Reproducible preclinical studies: Independent replication of key metabolic findings, including appropriate controls and clear exposure measurements.
• Mechanistic experiments: Studies that determine which pathways are necessary for specific biological effects rather than simply associated with them.
• Pharmacokinetic and safety research: Evaluation of exposure, metabolism, tolerability, immune responses, and potential toxicities.
• Controlled human trials: Randomized studies with prespecified outcomes, appropriate comparators, and sufficient follow-up.
• Clinically meaningful endpoints: Evidence that changes in metabolic biomarkers translate into relevant outcomes rather than remaining isolated laboratory observations.
• Transparent reporting: Publication of null findings, adverse events, protocol details, and uncertainty estimates as well as positive results.

A registered clinical trial is an important step because it describes a planned or ongoing evaluation. Its design, endpoints, enrollment, and eventual results must be assessed separately. A trial record without posted results cannot be used as evidence that the intervention works or is safe.

13. Frequently Asked Questions

14. Related Articles and Research Resources

• Vietnam Peptides Knowledge Hub — explore educational articles on peptide biology, mitochondrial signaling, and evidence interpretation.
• Peptide FAQ: Research, Storage, and Usage Questions — review general peptide terminology and research-related questions.
• Peptide Products Directory — browse the site’s commercial catalog. Listings should not be interpreted as evidence of clinical efficacy or regulatory approval.

15. Related Research Products

16. Scientific References

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009.
2. Wan W, Zhang L, Lin Y, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine. 2023;21:36. doi:10.1186/s12967-023-03885-2.
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. Full article.
4. Zhou Q, Yin S, Lei X, et al. The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2024;16:200. doi:10.1186/s13098-024-01405-w.
5. Merry TL, Chan A, Woodhead JST, et al. Mitochondrial-derived peptides in energy metabolism. American Journal of Physiology-Endocrinology and Metabolism. 2020. Full text.
6. U.S. Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting: briefing document for MOTS-c-related bulk drug substances, including MOTS-c free base and MOTS-c acetate. Official briefing document. This is an advisory-committee briefing document, not a final regulatory ruling.
7. Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c). Peer-reviewed review indexed in PubMed. PubMed record.
8. Kim SJ, et al. A mitochondrially encoded hormone ameliorates obesity and insulin resistance. Cell Metabolism. 2015. doi:10.1016/j.cmet.2015.02.013.

Conclusion

MOTS-c represents an important development in mitochondrial-derived peptide research because it suggests that the mitochondrial genome can encode signals involved in metabolic regulation beyond its traditional roles in cellular energy production.

The folate–purine–AMPK pathway provides the clearest mechanistic framework for understanding the original findings. Additional research proposes roles in mitochondrial retrograde signaling, stress-responsive gene expression, and exercise-related adaptation. These pathways offer plausible explanations for selected experimental observations, but their relative contributions and importance in human physiology remain uncertain.

Human studies measuring endogenous MOTS-c provide evidence that the peptide is associated with physiological and metabolic states, but those associations are not equivalent to treatment effects. Observational findings are not fully consistent, and animal studies cannot establish human efficacy or safety.

The central conclusion is therefore measured: MOTS-c is a biologically interesting mitochondrial-derived peptide with substantial preclinical research interest, but its proposed metabolic signaling pathways should not be confused with proven therapeutic benefits. Well-designed human trials, transparent safety reporting, and further mechanistic validation are needed before claims about clinical use can be supported.